| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Medivation, Astellas submit enzalutamide NDA to FDA | | 6 | Pharma Bus Review |
| 22.05.
| Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy | | 81 | MarketWire |
| SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 05/21/12 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced that Medivation has submitted a New Drug Application (NDA)...
Mehr lesen zu:
Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy | |
| 18.05.
| Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012 | | 44 | MarketWire |
| SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 05/18/12 -- Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that six abstracts related to enzalutamide (formerly MDV3100) will...
Mehr lesen zu:
Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012 | |
| 17.05.
| Astellas, AVEO announce positive results from TIVO-1 advanced RCC study | | 2 | Pharma Bus Review |
| 17.05.
| AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC | | 65 | Business Wire |
| - Tivozanib is the First Agent to Demonstrate Greater than One Year
PFS in Patients without Prior Systemic Treatment -
- First Pivotal Trial vs. Active Targeted...
Mehr lesen zu:
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC | |
| 17.05.
| Astellas & AVEO: Tivozanib Successfully Demonstrates the Longest Reported Progression-Free Survival in First Line Metastatic Renal Cell Carcinoma (RCC)1 | | 50 | Business Wire |
| Astellas and AVEO confirm that tivozanib achieved median
progression-free survival of 11.9 months in phase III first line
superiority trial1
...
Mehr lesen zu:
Astellas & AVEO: Tivozanib Successfully Demonstrates the Longest Reported Progression-Free Survival in First Line Metastatic Renal Cell Carcinoma (RCC)1 | |
| 08.05.
| Medigene erhält Meilensteinzahlung in Höhe von 5 Mio. EUR von Astellas | | 99 | Bionity.com |
| 07.05.
| Astellas announces favorable court ruling in Tarceva patent infringement suit | | 4 | Pharma Bus Review |
| 07.05.
| MediGene AG: Medigene erhält Meilensteinzahlung in Höhe von 5 Mio. EUR von Astellas | | 196 | Thomson Reuters ONE-DE |
| MediGene AG /
Medigene erhält Meilensteinzahlung in Höhe von 5 Mio. EUR von Astellas
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich....
Mehr lesen zu:
MediGene AG: Medigene erhält Meilensteinzahlung in Höhe von 5 Mio. EUR von Astellas | |
| 07.05.
| MediGene AG: Medigene Receives EUR 5 Million Milestone Payment from Astellas | | 67 | Thomson Reuters ONE |
| MediGene AG /
Medigene Receives EUR 5 Million Milestone Payment from Astellas
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement....
Mehr lesen zu:
MediGene AG: Medigene Receives EUR 5 Million Milestone Payment from Astellas | |
| 25.04.
| Astellas and Drais Partner to Develop Astellas Compound Through Telsar / InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $14 Million Into Telsar to Advance Compound | | 91 | MarketWire |
| TOKYO and BRIDGEWATER, NJ -- (Marketwire) -- 04/24/12 -- Astellas Pharma Inc. (TSE: 4503) ("Astellas") and Drais Pharmaceuticals, Inc. ("Drais") today announced that they have entered into a uniquely...
Mehr lesen zu:
Astellas and Drais Partner to Develop Astellas Compound Through Telsar / InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $14 Million Into Telsar to Advance Compound | |
| 17.04.
| INC RESEARCH, LLC: INC Research Announces Multi-Year Strategic Clinical Development Alliance with Astellas | | 43 | Thomson Reuters ONE |
| FSP alliance outsources highly specialized tasks across drug development pipeline to drive global consistency and deliver significant time and cost savings Raleigh, N.C., April 17, 2012 - INC Research...
Mehr lesen zu:
INC RESEARCH, LLC: INC Research Announces Multi-Year Strategic Clinical Development Alliance with Astellas | |
| 09.04.
| UPDATE 1-Astellas FY12 oper profit likely to climb 7 pct - Nikkei | | 5 | Reuters.com |
| 05.04.
| FDA Advisory Committee Recommends Approval of Mirabegron - Investigational Overactive Bladder Treatment from Astellas | | 105 | PR Newswire |
| DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive Health...
Mehr lesen zu:
FDA Advisory Committee Recommends Approval of Mirabegron - Investigational Overactive Bladder Treatment from Astellas | |
| 05.04.
| UPDATE 1-U.S. FDA panel backs Astellas drug for leaky bladder | | 1 | Reuters.com |
| 05.04.
| US FDA panel backs Astellas drug for leaky bladder | | 3 | Reuters.com |
| 03.04.
| FDA staff focus on safety of Astellas bladder drug | | 6 | Reuters.com |
| 02.04.
| Vical (VICL), Astellas Pharma Finalize TransVax Phase 3 Design | | 16 | StreetInsider.com |
| 29.03.
| Optimer Pharma (OPTR), Astellas Enter Licensing Agreement for CDI Treatment, Fidaxomicin | | 2 | StreetInsider.com |
| 29.03.
| Optimer Pharmaceuticals and Astellas Pharma Enter Collaboration to Commercialize Fidaxomicin for Clostridium difficile Infection in Japan | | 2 | Benzinga.com |
